ABT

Abbott Laboratories
D

ABT

Arincen83/100B

Abbott Laboratories return on equity (ROE)

Abbott Laboratories's return on equity is 10.61%: net income of 5.43B USD over the last twelve months on shareholders' equity of 51.11B USD.

Today
10.61%
Average, 5 years
18.60%
Low, 5 years
10.61%
High, 5 years
28.12%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 5.43B ÷ 51.11B = 10.61%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

Why is Abbott Laboratories's return on equity so high?

Net margin
14.7%
profit on each dollar of sales
Asset turnover
0.51×
sales on each dollar of assets
Equity multiplier
1.66×
assets on each dollar of equity
Return on equity
12.5%
FY2025
  • FY202514.7% × 0.51 × 1.66 = 12.5%
  • FY202431.9% × 0.52 × 1.71 = 28.1%
  • FY202314.3% × 0.55 × 1.90 = 14.8%
  • FY202215.9% × 0.59 × 2.03 = 18.9%
  • FY202116.4% × 0.57 × 2.10 = 19.8%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)
Today10.61%
FY202531 Dec 202512.51%
FY202431 Dec 202428.12%
FY202331 Dec 202314.83%
FY202231 Dec 202218.90%
FY202131 Dec 202119.75%
FY202031 Dec 202013.71%
FY201931 Dec 201911.86%
FY201831 Dec 20187.76%
FY201731 Dec 20171.54%
FY201631 Dec 20166.69%
FY201531 Dec 20157.46%
FY201431 Dec 201410.61%
FY201331 Dec 201310.23%
FY201231 Dec 201222.32%
FY201131 Dec 201119.35%
FY201031 Dec 201020.40%
FY200931 Dec 200924.83%
FY200831 Dec 200827.08%
FY200731 Dec 200720.28%
FY200631 Dec 200612.22%
FY200531 Dec 200523.39%
FY200431 Dec 200422.17%
FY200331 Dec 200321.06%
FY200231 Dec 200226.20%
FY200131 Dec 200117.11%
FY200031 Dec 200032.51%
FY199931 Dec 199932.93%
FY199831 Dec 199840.84%
FY199731 Dec 199741.90%
FY199631 Dec 199639.04%
FY199531 Dec 199538.41%
FY199431 Dec 199437.45%
FY199331 Dec 199338.07%
FY199231 Dec 199237.01%
FY199131 Dec 199133.99%
FY199031 Dec 199034.08%
FY198931 Dec 198931.54%
FY198831 Dec 198830.51%
FY198731 Dec 198730.22%
FY198631 Dec 198630.38%
FY198531 Dec 198524.87%

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about Abbott Laboratories's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.